Removing array-specific batch effects in GWAS mega-analyses 1 by applying a two-step imputation workflow reveals 2 new associations for thyroid volume and goiter 3

- 4
- M. Kamal Nasr<sup>1,2</sup>, Eva König<sup>3</sup>, Christian Fuchsberger<sup>3</sup>, Sahar Ghasemi<sup>4</sup>, Uwe Völker<sup>2,5</sup>, Henry Völzke<sup>2,6</sup>, Hans J. Grabe<sup>1,7</sup>, Alexander Teumer<sup>1,2</sup> 5
- 6
- 7
- <sup>1</sup> Department of Psychiatry and Psychotherapy, University Medicine Greifswald, 8
- 9 Greifswald, Germany
- <sup>2</sup> DZHK (German Centre for Cardiovascular Research), Partner Site Greifswald, 10
- 11 Greifswald, Germany
- <sup>3</sup> Institute for Biomedicine, Eurac Research, Bolzano, Italy 12
- <sup>4</sup> Institute of Genetic Epidemiology, Medical Center University of Freiburg, Faculty 13
- of Medicine, University of Freiburg, Germany 14
- 15 <sup>5</sup> Interfaculty Institute for Genetics and Functional Genomics, University Medicine
- 16 Greifswald, Greifswald, Germany
- <sup>6</sup> Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17
- 18 Germanv
- <sup>7</sup> German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, 19
- 20 Greifswald, Germany
- 21
- 22 Keywords: genetic imputation, association studies, mega-analysis
- 23 Correspondence to:
- 24 Dr. Alexander Teumer
- 25 University Medicine Greifswald
- 26 Department of Psychiatry and Psychotherapy
- 27 Ellernholzstr. 1-2
- 28 17475 Greifswald, Germany
- ateumer@uni-greifswald.de 29
- Phone: +49 (0) 3834-86-6918 30
- 31 ORCiD: https://orcid.org/0000-0002-8309-094X
- 32
- 33

#### 34 Abstract

Background: Combining individual-level data in genetic association studies (megaanalyses) enhances statistical power for identifying gene-trait associations. However,
batch effects from combining variants of different arrays pose a major limitation.
Here, we developed a two-step imputation workflow to overcome the array type bias.

39 **Methods:** Genotype data of 10,647 individuals generated using five different arrays 40 were included. Intermediate array-specific panels were generated and subsequently 41 imputed against the 1000 Genomes Project Phase3 reference panel. Genetic 42 principal component (PC) analysis assessed batch effects in the cohort-combined 43 imputed data. The workflow's performance was evaluated by comparing imputation quality r<sup>2</sup> and allele frequency difference of the proposed two-step imputation to the 44 45 conventional array-specific imputation as well as its matching with a whole-genome 46 sequenced subgroup for further validation. We performed a genome-wide association 47 study (GWAS) to test for genetic associations with goiter risk and thyroid gland 48 volume, comparing summary statistics of both approaches.

**Results:** The proposed workflow eliminated the batch effect from the first twenty genetic PCs. The outcome of the workflow also showed high correlation with the conventional approach for allele frequencies ( $r^2 > 0.99$ ). GWAS results from the twostep imputation confirmed known associations on thyroid traits and revealed novel loci for thyroid volume (*TG, PAX8, IGFBP5, NRG1*), and one novel locus for goiter (*XKR6*), which was not statistically significant following the GWAS meta-analysis of conventional imputation.

56 Conclusion: Our imputation workflow provides high-quality imputation results without
57 technical batch effects, fostering mega-analysis involving multiple genotyping arrays
58 for different genetic association analysis.

- 59
- 60

#### 61 Introduction

62 Genome-wide association studies (GWAS) represent an agnostic approach for 63 identifying genetic associations with common traits and diseases by testing millions 64 of variants with continuous outcomes or between groups. The testing checks allele 65 frequency differences between individuals in a selected population that show different representations of the trait value <sup>1</sup>. GWAS analyses have been utilized in 66 more than 5,700 studies, exploring 3,300 different traits <sup>1,2</sup>. The results of these 67 68 analysis enriched our knowledge about disease risk variants, as well as identifying 69 individuals with high disease-risk profiles through risk scores for complex heritable 70 traits <sup>1,3</sup>.

71 The power to detect associations increases with sample size and number of variants 72 tested <sup>3,4</sup>, rare and low frequency single nucleotide variants (SNVs) are of high 73 interest. This requires the inclusion of large sample sizes in the experimental design, 74 which is complicated or even unrealistic for rare diseases and low number of cases in 75 the investigated populations. One alternative approach is a meta-analysis of 76 summary statistics from different GWAS analyses of the same trait, performed either 77 on same or different populations<sup>4,5</sup>. Another approach is to combine the individual-78 level data of samples from different cohorts to perform a mega-analysis <sup>6</sup>.

Meanwhile, genetic imputation is a reliable method to estimate alleles of variants not directly genotyped on an array. Based on linkage disequilibrium (LD), genetic imputation can significantly increase coverage of the human genome when using different commercial genotyping arrays <sup>7,8</sup>. This method is utilized as an alternative for expensive whole genome sequencing <sup>9</sup>.

84 GWAS on imputed variants and subsequent meta-analysis are frequently utilized cost-effective approaches for conducting large GWAS<sup>10</sup>, however, they are also 85 86 associated with technical limitations <sup>11</sup>. If the sample size or number of cases in a 87 specific cohort especially in a (nested) case-control design is low, the analysis results 88 are less reliable because the effective number of samples is too small for the 89 association models like linear regression, logistic regression or mixed-effects models, 90 particularly when it comes to low-frequency variants. In addition, the analysis 91 workload substantially increases with the number of cohorts included in a project 12.

92 Former studies have shown that both meta-analyses and mega-analyses using 93 individual participant data are mathematically equivalent <sup>13</sup>, and also comparable when using imputed genotypes <sup>14</sup>. However, previous studies have mainly focused
on data from cohorts genotyped on the same array type. Highlighting challenges in
mega-analysis, where individual-level data from multiple cohorts genotyped on
different arrays are combined.

We identified a concerning technical bias when combining the imputed data of individuals from genetically homogeneous northeastern German cohorts that were genotyped using diverse array types <sup>15,16</sup>. Principal component analysis (PCA) conducted on the quality-controlled genotype data revealed variation influenced by the array type. Notably, this variation was detected upon both imputation against the haplotype reference consortium (HRC) <sup>17</sup> and the 1000 Genomes v5 (1000G) reference panels <sup>18</sup>.

105 Here, we propose a newly developed workflow, to minimize the technical bias due to 106 batch effect when combining genotype data from different arrays. The workflow is 107 composed of two imputation steps. First we impute the included genotype datasets 108 pairwise against each other and then create a panel of overlapping variants for each 109 imputation outcome. Finally, we impute the generated intermediate panel against one 110 of the commonly available large panels. We evaluate the outcome of the new 111 workflow in comparison to conventional imputation approaches. In an application 112 example, we conducted a GWAS analysis on thyroid gland volume and goiter, 113 identifying new associations with goiter while demonstrating the robustness of our 114 imputation workflow by validating known associations.

#### 115 Materials and Methods

#### 116 Workflow design overview

117 In this project, three different approaches for genetic imputation have been 118 conducted. The first proposed approach is a new two-step imputation process. The 119 second and third approaches are conventional single-step imputation for comparison 120 with the newly proposed method. We modified the third approach to be a single-step 121 imputation using only the intersecting variants genotyped on all included array types. 122 The genotype data that were used for imputation were the same in both imputation 123 approaches. We used data from five different arrays (Affymetrix SNP 6.0, Affymetrix 124 Axiom [Thermo Fisher Scientific, Santa Clara, CA, USA], and Illumina Omni 2.5, 125 Illumina GSA, and Illumina PsychArray [Illumina, Inc., San Diego, CA, USA]) 126 obtained from samples of the German GANI MED (n= 2410), SHIP-START (n=

4070) and SHIP-TREND (n= 4119) (Figure 1) <sup>15,16</sup>. The individuals genotyped on the Affymetrix Axiom array (n= 48) were a subset of the Affymetrix SNP 6.0 samples, whereas all other individuals were genotyped only once. Detailed information regarding the included datasets, sample sizes, and genotype arrays are provided in Figure 1 and the Supplementary Methods. For evaluation of the imputation performance, a whole-genome sequenced subset of 192 individuals from SHIP-TREND has been used for genotype matching concordance checking.

#### 134 Data pre-processing and phasing

Genotype quality control was performed using PLINK<sup>19</sup> as reported previously<sup>20,21</sup>. 135 136 Briefly, arrays with genotype call rate <94%, as well as variants with missing call rate >5%, Hardy-Weinberg equilibrium p-value  $<10^{-4}$ , and monomorphic SNVs and 137 138 singletons were excluded. All the included genotype datasets were aligned to 139 reference genome build (GRCh37) using BCFtools software followed by retaining only sites with at least one alternative allele <sup>22</sup>. Haplotype phasing preceding the first 140 141 imputation round was performed for each genotype dataset using Eagle2 (5 phasing 142 iterations and number of conditioning haplotypes =  $10^4$ ) and estimated to hq19 143 mapping<sup>23</sup>. No external reference panel was used for phasing.

#### 144 Two-step imputation

145 In the first step, the intermediate imputation, each phased panel was used as a reference panel after compression with the minimac4 imputation software <sup>24</sup>. Each of 146 147 the five pre-processed genotype arrays was imputed pairwise against the other four. 148 yielding twenty imputed datasets. Using an R scripted algorithm with VCFtools and BCFtools for variants filtration<sup>22</sup>, each of these imputed variant sets were subset to 149 150 the variants overlapping between all generated panels with high imputation quality 151  $(R^2 \ge 0.9)$ , selecting the source panel with the highest imputation quality score for 152 each variant. The outcome of the first-step imputation was one VCF file for each 153 cohort dataset, which was then used as input for the second imputation step against 154 1000G reference panel using the Michigan imputation server <sup>24</sup>. Eagle2 was selected 155 for phasing without (additional) imputation guality filters applied at this stage of the 156 imputation.

#### 157 Conventional imputation

To validate the outcome of the proposed workflow, we imputed the genotype data of each array directly against 1000G reference panel using the same parameters and quality control procedures as described in the two-step imputation.

161 Conventional imputation with overlapping genotypes

To evaluate a simple approach for removing the array type specific batch effect, we ran a single-step imputation by restricting the input variants to those assessed on all array types. This approach was tested for three (Affymetrix SNP 6.0, Illumina Omni 2.5 and Illumina GSA) and all five array types. We compared the imputation quality of these imputations to the conventional and the two-step imputation exemplarily for the SHIP-TREND.

### 168 Batch effect assessment

169 Technical bias was assessed by estimating genetic principal components of the 170 imputed and quality-controlled genotype data. Quality control filters included missing 171 variant call rates above 5%, Hardy-Weinberg equilibrium p-values less than 10<sup>-4</sup>, 172 minor allele frequency (MAF) less than 1%, correlated variants were removed by LD pruning with a window size of 50, step size of 5 SNVs and  $R^2$  threshold of 0.2. 173 174 Genetic principal components, along with their explained variances were compared 175 between two-step imputation and conventional imputation. To check the robustness 176 of the two-step imputation approach for rare variants, we further ran PCA on rare 177 variants (MAF < 1%). All PCAs are performed using PLINK 2.0 software <sup>19</sup>. Principal 178 components (PC) of the first twenty components were plotted with ggplot2 package 179 of R software.

## 180 Evaluation of imputation performance

Genotype data attributes, including differences in MAF and imputation quality R<sup>2</sup> measure between the two-step and conventional imputation were compared for each included cohort after stratification by minor allele frequency. We additionally checked the concordance (number of matching genotypes/total number of genotypes <sup>25</sup>) of the imputed best-guess (hard call) genotypes with their whole-genome sequencing data of a subset of 192 individuals from SHIP-TREND (Omni 2.5) for which whole genome sequencing (WGS) data was also available.

#### 188 GWAS and results comparison

We evaluated the results of GWAS analyses using genotype dosage information from both two-step and conventional imputation approaches using thyroid gland volume and goiter risk as outcomes as described before <sup>26</sup>, and summarized in the Supplementary Methods.

193 All GWAS were conducted with the EPACTS 3.3.2 software using dosages <sup>27</sup>. 194 Inverse-variance weighted meta-analysis of the single cohort GWAS summary statistics based on the conventional imputation approach was done using the METAL 195 software <sup>4</sup>. We compared the summary statistics p-values, effect estimates and its 196 197 standard errors. A detailed description of the GWAS analysis plan is available in the 198 Supplementary Methods. Independent (lead) variants associated with thyroid traits 199 were identified using the clumping function of PLINK with a threshold of  $p < 5 \times 10^{-8}$ , 200  $r^2 > 0.01$  and 1 Mb distance, and compared across the imputation approaches. For 201 biological validation of the findings, lead variants were investigated by checking their 202 association with thyrotropin to support their biological plausibility <sup>20</sup>.

#### 203 Results

204 Genotype datasets of 10,647 individuals genotyped on five different array types were 205 included in the workflow (Figure 1). After the intermediate imputation, 1,942,499 high-206 quality overlapping autosomal variants were generated for each of the included five 207 datasets, and subsequently used for the second imputation step against the 1000G 208 reference panel. In contrast, only 58,091 autosomal genotyped variants were 209 available as imputation input in the three cohorts using the conventional imputation 210 approach with overlapping variants. This number further dropped to 12,265 variants 211 when including the Affymetrix Axiom and Illumina PsychArrays. Supplementary Table 212 1 provides the distribution of these variants for each chromosome in the two-step 213 imputation, the conventional imputation and conventional imputation using 214 overlapped variants.

## 215 Batch effect investigation (PCA analysis)

For the conventional imputation, 939,802 variants with a total genotyping rate of 0.988 were included in the PCA analysis, with 2,314,205 variants removed due to missing genotype threshold, 9,118 variants due to Hardy-Weinberg equilibrium, and 38,008,458 variants due to the MAF threshold. Projecting the first two principle

components of the imputed genotypes clustered the samples by array types with a combined explained variance of 0.242 (Figure 2a, b, Supplementary Figure 1a).

222 The two-step imputation included 1.360.834 variants with a total genotyping rate of 223 0.989 in the PCA analysis after removing 725,008 variants due to missing genotype 224 threshold, 5,363 variants due to Hardy-Weinberg equilibrium, and 37,753,448 225 variants due to the MAF threshold. Using this approach, the first 20 principal 226 components of the imputed genotypes did not show any array type specific clusters 227 (Figure 2c, d, Supplementary Figure 1b). PCA restricted to the rare genotypes 228 imputed with the two-step approach did not show clustering by the array type 229 (Supplementary Figure 2).

230 The conventional imputation using only overlapping variants also removed the batch 231 effect (Supplementary Figure 3), but led to a drastic decrease in the quality of the 232 imputed variants for all allele frequency groups in comparison to the other approaches (Supplementary Figure 4). Median  $R^2$  of the overlapping variants was 233 234 0.011, while for two-step imputation and conventional imputation using all variants 235 was 0.993 for variants with MAF > 0.05, which was the main reason for not 236 considering this approach any further in the performance evaluation and GWAS 237 analysis, focusing only on the two-step imputation against conventional imputation 238 using all variants.

239 Two-step imputation outcome parameters comparison with conventional imputation

240 Our newly developed two-step imputation approach showed higher overall guality for 241 the imputation outcome of rarer variants (MAF < 0.01) than the conventional 242 imputation (Figure 3, Supplementary Figure 5). For less-common variants with MAF between 0.04 and 0.05, the median  $R^2$  increased by 0.19 when using the two-step 243 244 imputation approach for the GANI MED Illumina PsychArray. It also shows 245 comparable allele frequencies to the conventional approach, judging by the absolute 246 difference in allele frequencies for each imputed variant in both approaches (Figure 247 4). Detailed statistics about median  $R^2$  and MAF differences are presented in 248 Supplementary Table 2.

Hard call genotype concordance results in the subgroup of SHIP-TREND with matching WGS data showed strong correlation between two-step imputation and sequenced genotypes. The Pearson correlation coefficients with the homozygous

reference, heterozygous, and homozygous alternative genotypes were 0.996, 0.981,

and 0.979, respectively (Table 1, Supplementary Figure 6).

254 GWAS on thyroid traits

A total number of 6,894 individuals from SHIP-START and SHIP-TREND (both array types) with thyroid measurement information were included in the GWAS analysis, all participants were of European ancestry. Detailed information about cohort characteristics is presented in Table 2. The estimated genomic control for all conducted GWAS analysis showed no signs of inflation, with a minimum and maximum  $\square_{GC} = 1.001$  and 1.038, respectively (Supplementary Figure 7).

261 Meta-analysis of the GWAS analysis on goiter risk using conventionally imputed 262 genotypes revealed four significantly associated loci ( $p < 5 \times 10^{-8}$ ). Confirming the results from previously conducted GWAS analysis<sup>26</sup>. Two of the loci are located at 263 264 the CAPZB region in chromosome 1, the other two at the FAM227B and MAFTRR 265 regions on chromosome 15 and 16, respectively (Figure 5b). However, the GWAS 266 analysis of the combined two-step imputed genotype data revealed another 267 associated locus at the XKR6 region on chromosome 8 (Figure 5c), which did not 268 attain statistical significance using the conventional meta-analysis approach (Figure 269 5a).

270 The conventional approach of the GWAS meta-analysis of thyroid volume revealed 271 four novel associations at the PAX8 region on chromosome 2, at IGFBP5, NRG1 and 272 TG (Figure 6b,c), and confirmed all known associations with this trait<sup>20</sup>. Genome-273 wide significance for these regions were also obtained with the GWAS using the 274 combined two-step imputed genotype data, with the exception of NRG1 (p-value = 275 5.22 x  $10^{-8}$ ). (Figure 6a). Except the *PAX8* region, all associated loci were also 276 associated with thyroxin in recently published multi-trait GWAS meta-analysis 277 analysis for thyroid function <sup>20</sup>.

Table 3 summarizes the results of the SNVs with the strongest association of both GWAS approaches and traits. The significant GWAS results of both approaches were comparable, judging by the magnitude of the estimates. However, the standard errors of the GWAS results obtained from the two-step imputed genotypes where generally lower, where the natural log p-values were slightly higher in the linear regression and lower in the logistic regression based analyses compared to the conventional imputation and subsequent meta-analysis. (Supplementary Figures 8 and 9).

#### 285 Discussion

286 Genome-wide association studies have helped identify genetic factors for many traits and diseases. Since the 1960s, collecting genotype samples from diverse 287 populations has grown in importance <sup>28,29</sup>. Imputation techniques now address gaps 288 in whole-genome sequencing <sup>30</sup>. However, variations in these methods across 289 290 cohorts reduce the accuracy of genetic analyses due to biases from differing array technologies <sup>31,32</sup>. For instance, in our genotyped samples where we compared the 291 292 allele frequencies of the SHIP-TREND subgroup genotyped using Illumina Omnia 2.5 293 with the corresponding whole genome sequencing variants (Supplementary Figure 294 10), this array-specific variation in the allele frequency, both in common and rare 295 variants, can affect LD estimation in haplotype phasing and genotype imputation. Our 296 newly developed imputation method addresses the additional variation induced by 297 including multiple array types. By forming an intermediate panel of high-quality 298 variants, the method enables high imputation accuracy while removing the array type 299 induced batch effects.

The developed workflow was inspired by the use of only overlapping variants in the included cohorts (Supplementary Table 1), which eliminated the observed bias, yet led to a significant decrease in the imputation quality due to removal of informative tag SNVs (Supplementary Figure 3), the influence of informative SNVs on imputation quality has been shown in previous research work <sup>33</sup>. Based on that, we introduced an intermediate imputation step to generate a panel that can retain the same genotype information of the included arrays and thus preserving its LD structure.

Selecting an appropriate threshold for the imputation  $R^2$  ( $\geq 0.9$ ) of the overlapping 307 308 variants in the intermediate panel was essential for having reliable genotype 309 information upon imputing against 1000G panel. The value of the threshold was 310 decided following the output of several imputations using different thresholds. We aimed to use the highest possible value for imputation guality  $R^2$  without affecting 311 312 haplotype phasing results due to removing too many variants. Supplementary Table 1 shows the number of included variants per chromosome when the R<sup>2</sup> threshold 313 314 was adjusted to 0.8 as well as 0.9. Both approaches led to similar imputation outputs 315 as seen after plotting genetic PCs of the imputation outcomes (Figure 2 and 316 Supplementary Figure 11).

317 To evaluate the existence of the array type bias, we used genetic PCs to capture the 318 main variance in the allele frequencies, which can be seen as the influence of the 319 array type after projecting the PCs of the eigenvectors and evaluate the homogeneity 320 of the projected points on PC axis <sup>34</sup>. The imputation following the developed two-321 step approach showed its capability to overcome the array type differentiation 322 whenever existing in the first twenty components, compared to conventional 323 imputation outcomes where a clear clustering effect by the array type was observed 324 (Figure 2).

325 To test the performance of the imputation outcomes, we focused on comparing allele 326 frequency and imputation quality parameters of the cohort genotypes. These 327 parameters are particularly relevant for conducting trait-association studies. The 328 developed imputation flow showed strong matching of the allele frequency, 329 represented by minimized difference in allele frequency for each variants between 330 the imputation approaches (Figure 4 and Supplementary Table 2). The developed 331 imputation workflow was successful in providing more reliable genetic predictions for 332 imputed rarer alleles (Figure 3). Moreover, a strong correlation in the median  $R^2$  of 333 the two imputation approaches using the SHIP-TREND Omni 2.5 arrays was 334 observed in comparison to other cohorts. This could be due to the high variant 335 coverage of the array used for genotyping the cohort's samples. Further analysis of 336 the allele frequency variance for each variant from both imputation outcomes of this 337 specific cohort shows the strong correlation in the autosomal allele frequency (correlation  $r^2$  >0.999) (Supplementary Figure 12). Nevertheless, SHIP-TREND 338 339 imputed genotypes showed strong concordance with the corresponding genotyped 340 variants in the whole-genome sequenced subgroup, indicating the representation of 341 well estimated genotypes in both rarer and common variants (Table 1 and 342 Supplementary Table 3). Using the allele frequencies of the WGS subgroup as a gold 343 standard for comparison of the imputation results is somewhat misleading because 344 differences in the genotype frequencies exist already between genotyped variants on 345 the arrays and the WGS (Supplementary Figure 10).

The aim of conducting GWAS as part of the imputation workflow evaluation is to compare regression analyses results of the combined two-step imputed datasets to the conventional inverse-variance meta-analysis of the same samples. Goiter risk and thyroid volume are both suitable traits for our evaluation as they represent different trait datatypes with a true positive genetic association in SHIP <sup>26</sup>. The results

351 of GWAS analysis for the two-step imputed data showed two key advantages. First, 352 we were able to identify a new association in the XKR6 gene region with goiter risk 353 as a dichotomous trait which did not reach statistical significance in the conventional 354 meta-analysis. Variants in this locus were also associated with thyroxin in a former GWAS, making this association biologically reasonable <sup>20</sup>. A slightly better 355 356 performance of the mega-analysis vs. a meta-analysis for a logistic regression GWAS is in line with the results of a former study <sup>14</sup>. The second point was its 357 358 consistency with conventional imputation GWAS meta-analysis in revealing a novel 359 locus associated with thyroid gland volume (PAX8). PAX8 is a paired box family gene 360 member that was found to be associated with the development of thyroid gland in 361 embryonic development, and its transcription is a diagnostic marker for anaplastic thyroid carcinoma <sup>35–37</sup>, and thus represents also a plausible association with thyroid 362 363 volume in adults. All other significant GWAS findings represent also plausible true 364 positive associations as they confirmed former findings of these traits (including replication in an independent cohort)<sup>26</sup>, or were associated with thyroid function<sup>20</sup>. 365

The comparison of the estimates and standard errors of both GWAS approaches did not show signs of p-value inflation. However, it showed that the GWAS of the twostep imputation data had a slight decrease in standard errors, in comparison to the meta-analysis outcomes.

370 Besides its role in discovering more hits in case-control GWAS analysis, our 371 developed two-step imputation workflow is not restricted to a specific array, the 372 inclusion of different arrays with different sequencing technologies in the workflow 373 has proven its robustness in overcoming the array bias regardless of the number or 374 the type of the array. It is also applicable for other generalized imputation panels like TOPMed or HRC reference panels <sup>24</sup>. These two strengths shall enable the utilization 375 376 of combined genotype information for better understanding of rare diseases or 377 genetic associations in populations that are represented in small sample sizes.

Although the array type specific batch effect in GWAS mega-analyses might be reduced in specific scenarios by adjusting for genetic PCs, such a correction will not be possible in all analyses. Such analyses include the ones using polygenic scores. Our two-step imputation provides a powerful solution for combining datasets while reducing technical bias also for analyses of polygenic scores. 383 Comparing the imputation outcomes to the whole genome-sequenced data had 384 limitations for evaluating the proposed workflow, either due to the relatively small 385 sample size of individuals who underwent WGS (n = 192 after QC) and its exclusivity 386 for one of the included five cohorts. Although the total sample size provided us the 387 possibility of analysing low frequency alleles, it was likely too small for evaluating the 388 performance of the different approaches for very rare alleles. However, our two-step 389 imputation approach seems to be on average superior to the classical imputation with 390 regard to the imputation quality measure (Figure 3), while the difference in allele 391 frequency is small particularly for rarer variants (Figure 4 and Supplementary Table 392 2). As indicated also in these results, the average difference in allele frequency 393 seems to depend also on the density and design of the underlying genotyping array.

394 While the imputed genotypes generated from the proposed workflow will be utilized 395 for identifying novel genetic associations in SHIP and GANI-MED, it will be interesting 396 to evaluate the impact of the developed workflow on other cohorts, especially those 397 comprising diverse ancestries. Thus far, all the included cohorts are of European 398 ancestry from the North-East of Germany, highlighting the need to test the workflow's 399 efficacy on genotyped cohorts from other or multiple genetic ancestries. Such 400 evaluations will help to determine the generalizability and robustness of the 401 imputation method across different genetic backgrounds, ultimately enhancing its 402 utility in global genomic research.

403 In conclusion, our developed two-step imputation workflow aims to overcome the 404 array type bias, by creating an intermediate panel of high-guality overlapping imputed 405 variants. This approach enables the conduction of mega-analysis by combining 406 genotype information from different arrays without inducing a technical array type 407 effect. Our workflow will increase statistical power for conducting large-scale GWAS 408 mega-analyses and other genetic analyses like polygenic risk score calculations, 409 playing an important role in genetic research and its application in individualized 410 medicine.

411

### 412 Acknowledgements:

SHIP is part of the Community Medicine Research net of the University of Greifswald,
Germany, which is funded by the Federal Ministry of Education and Research (grants
no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as

416 the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the 417 network 'Greifswald Approach to Individualized Medicine (GANI\_MED)' funded by the 418 Federal Ministry of Education and Research (grant 03IS2061A). Genome-wide data 419 have been partly supported by the Federal Ministry of Education and Research (grant 420 no. 03ZIK012) and a joint grant from Siemens Healthineers, Erlangen, Germany and 421 the Federal State of Mecklenburg- West Pomerania. The project is funded by the 422 Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -423 455978266 (A.T.). The authors are grateful to Linda Garvert for testing and helpful 424 feedback on the two-step imputation workflow.

## 425 Author Contributions:

- 426 Project design and supervision: A.T.
- 427 Analyses: M.K.N., E.K., S.G.
- 428 Interpretation of the results: M.K.N., A.T., E.K., C.F.
- 429 Drafting of the manuscript: M.K.N., A.T.
- 430 Providing genotype and phenotype data: U.V., H.V., H.J.G
- 431 Critical review of the manuscript: all authors

## 432 Data and code availability

433 Developed scripts for the workflow available on github are 434 (https://github.com/GenEpi-psych-UMG/Two Step Imputation). The data of the SHIP 435 study cannot be made publically available due to the informed consent of the study 436 participants, but it can be accessed through a data application form available at 437 https://transfer.ship-med.uni-greifswald.de/ for researchers who meet the criteria for 438 access to confidential data. The full results of the GWAS summary statistics are 439 available on the ThyroidOmics Consortium website (http://www.thyroidomics.com).

## 440 **Consents and approvals**

The study followed the recommendations of the Declaration of Helsinki. The medical ethics committee of the University of Greifswald approved the study protocol, and oral and written informed consents were obtained from each of the study participants.

## 444 **Conflicts of interest**

The authors have no affiliation with any organization with a direct or indirect financial

446 interest in the subject matter discussed in the manuscript. HJG received travel grants

- 447 and speakers honoraria from Neuraxpharm, Servier, Indorsia and Janssen Cilag not
- 448 related to the current project. HV received travel grants and speakers honoraria from
- 449 Sanofi-Aventis not related to the current project.

450

## 452 **References**

- 453 Uffelmann, E., Huang, Q.Q., Munung, N.S., de Vries, J., Okada, Y., Martin, 1. 454 A.R., Martin, H.C., Lappalainen, T., and Posthuma, D. (2021). Genome-wide 455 association studies. Nat. Rev. Methods Prim. 1. 59. 456 https://doi.org/10.1038/s43586-021-00056-9.
- Watanabe, K., Stringer, S., Frei, O., Umićević Mirkov, M., de Leeuw, C.,
  Polderman, T.J.C., van der Sluis, S., Andreassen, O.A., Neale, B.M., and
  Posthuma, D. (2019). A global overview of pleiotropy and genetic architecture
  in complex traits. Nat. Genet. *51*, 1339–1348. https://doi.org/10.1038/s41588019-0481-0.
- Khera, A. V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H.,
  Natarajan, P., Lander, E.S., Lubitz, S.A., Ellinor, P.T., et al. (2018). Genomewide polygenic scores for common diseases identify individuals with risk
  equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224.
  https://doi.org/10.1038/s41588-018-0183-z.
- 467 4. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta468 analysis of genomewide association scans. Bioinformatics 26, 2190–2191.
  469 https://doi.org/10.1093/bioinformatics/btq340.
- 470 5. Mägi, R., Horikoshi, M., Sofer, T., Mahajan, A., Kitajima, H., Franceschini, N.,
  471 McCarthy, M.I., COGENT-Kidney Consortium, T2D-GENES Consortium, A.P.,
  472 and Morris, A.P. (2017). Trans-ethnic meta-regression of genome-wide
  473 association studies accounting for ancestry increases power for discovery and
  474 improves fine-mapping resolution. Hum. Mol. Genet. *26*, 3639–3650.
  475 https://doi.org/10.1093/hmg/ddx280.
- Abou-Khalil, B., Auce, P., Avbersek, A., Bahlo, M., Balding, D.J., Bast, T., 476 6. 477 Baum, L., Becker, A.J., Becker, F., Berghuis, B., et al. (2018). Genome-wide 478 mega-analysis identifies 16 loci and highlights diverse biological mechanisms 479 in the common epilepsies. Nat. Commun. 9. 5269. 480 https://doi.org/10.1038/s41467-018-07524-z.
- 481 7. Burton, P.R., Clayton, D.G., Cardon, L.R., Craddock, N., Deloukas, P.,
  482 Duncanson, A., Kwiatkowski, D.P., McCarthy, M.I., Ouwehand, W.H., Samani,
  483 N.J., et al. (2007). Genome-wide association study of 14,000 cases of seven
  484 common diseases and 3,000 shared controls. Nature 447, 661–678.
  485 https://doi.org/10.1038/nature05911.
- 486
  486
  487
  487
  488
  488
  488
  488
  489
  480
  480
  480
  480
  481
  481
  482
  483
  484
  484
  485
  485
  486
  486
  487
  487
  488
  488
  488
  489
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
  480
- 490
  9. Quick, C., Anugu, P., Musani, S., Weiss, S.T., Burchard, E.G., White, M.J.,
  491
  491
  492
  492
  493
  493
  494
  494
  494
  495
  494
  496
  497
  498
  498
  499
  499
  499
  490
  490
  490
  490
  490
  491
  491
  492
  493
  494
  494
  494
  494
  495
  494
  496
  497
  498
  498
  499
  499
  499
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  490
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  400
  <li
- Pasaniuc, B., Rohland, N., McLaren, P.J., Garimella, K., Zaitlen, N., Li, H.,
  Gupta, N., Neale, B.M., Daly, M.J., Sklar, P., et al. (2012). Extremely lowcoverage sequencing and imputation increases power for genome-wide
  association studies. Nat. Genet. *44*, 631–635. https://doi.org/10.1038/ng.2283.
- 499 11. Palmer, C., and Pe'er, I. (2016). Bias Characterization in Probabilistic
  500 Genotype Data and Improved Signal Detection with Multiple Imputation. PLOS
  501 Genet. *12*, e1006091. https://doi.org/10.1371/journal.pgen.1006091.
- 502 12. Winkler, T.W., Day, F.R., Croteau-Chonka, D.C., Wood, A.R., Locke, A.E.,

- 503 Mägi, R., Ferreira, T., Fall, T., Graff, M., Justice, A.E., et al. (2014). Quality 504 control and conduct of genome-wide association meta-analyses. Nat. Protoc. *9*, 505 1192–1212. https://doi.org/10.1038/nprot.2014.071.
- Lin, D.Y., and Zeng, D. (2010). On the relative efficiency of using summary
  statistics versus individual-level data in meta-analysis. Biometrika *97*, 321–332.
  https://doi.org/10.1093/biomet/asq006.
- 509 14. Gorski, M., Günther, F., Winkler, T.W., Weber, B.H.F., and Heid, I.M. (2019).
  510 On the differences between mega- and meta-imputation and analysis
  511 exemplified on the genetics of age-related macular degeneration. Genet.
  512 Epidemiol. 43, 559–576. https://doi.org/10.1002/gepi.22204.
- 513 15. Völzke, H., Schössow, J., Schmidt, C.O., Jürgens, C., Richter, A., Werner, A.,
  514 Werner, N., Radke, D., Teumer, A., Ittermann, T., et al. (2022). Cohort Profile
  515 Update: The Study of Health in Pomerania (SHIP). Int. J. Epidemiol.
  516 https://doi.org/10.1093/ije/dyac034.
- 517 16. Grabe, H.J., Assel, H., Bahls, T., Dörr, M., Endlich, K., Endlich, N., Erdmann,
  518 P., Ewert, R., Felix, S.B., Fiene, B., et al. (2014). Cohort profile: Greifswald
  519 approach to individualized medicine (GANI\_MED). J. Transl. Med. *12*, 144.
  520 https://doi.org/10.1186/1479-5876-12-144.
- McCarthy, S., Das, S., Kretzschmar, W., Delaneau, O., Wood, A.R., Teumer,
  A., Kang, H.M., Fuchsberger, C., Danecek, P., Sharp, K., et al. (2016). A
  reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48,
  1279–1283. https://doi.org/10.1038/ng.3643.
- 18. 1000 Genomes Project Consortium, A., Auton, A., Brooks, L.D., Durbin, R.M.,
  Garrison, E.P., Kang, H.M., Korbel, J.O., Marchini, J.L., McCarthy, S., McVean,
  G.A., et al. (2015). A global reference for human genetic variation. Nature *526*,
  68–74. https://doi.org/10.1038/nature15393.
- 529 19. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J.
  530 (2015). Second-generation PLINK: rising to the challenge of larger and richer
  531 datasets. Gigascience *4*, 7. https://doi.org/10.1186/s13742-015-0047-8.
- 532 20. Sterenborg, R.B.T.M., Steinbrenner, I., Li, Y., Bujnis, M.N., Naito, T., Marouli, 533 E., Galesloot, T.E., Babajide, O., Andreasen, L., Astrup, A., et al. (2024). Multi-534 trait analysis characterizes the genetics of thyroid function and identifies causal 535 associations with clinical implications. Nat. Commun. 15, 888. 536 https://doi.org/10.1038/s41467-024-44701-9.
- 537 21. Teumer, A., Tin, A., Sorice, R., Gorski, M., Yeo, N.C., Chu, A.Y., Li, M., Li, Y.,
  538 Mijatovic, V., Ko, Y.-A., et al. (2016). Genome-wide Association Studies Identify
  539 Genetic Loci Associated With Albuminuria in Diabetes. Diabetes *65*, 803–817.
  540 https://doi.org/10.2337/db15-1313.
- 541 22. Danecek, P., Bonfield, J.K., Liddle, J., Marshall, J., Ohan, V., Pollard, M.O.,
  542 Whitwham, A., Keane, T., McCarthy, S.A., Davies, R.M., et al. (2021). Twelve
  543 years of SAMtools and BCFtools. Gigascience 10.
  544 https://doi.org/10.1093/gigascience/giab008.
- Loh, P.-R., Danecek, P., Palamara, P.F., Fuchsberger, C., A Reshef, Y., K
  Finucane, H., Schoenherr, S., Forer, L., McCarthy, S., Abecasis, G.R., et al.
  (2016). Reference-based phasing using the Haplotype Reference Consortium
  panel. Nat. Genet. *48*, 1443–1448. https://doi.org/10.1038/ng.3679.
- 549 Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, 24. 550 S.I., Chew, E.Y., Levy, S., McGue, M., et al. (2016). Next-generation genotype 551 imputation service and methods. Nat. Genet. 48. 1284–1287. 552 https://doi.org/10.1038/ng.3656.
- 553 25. Wuttke, M., König, E., Katsara, M.-A., Kirsten, H., Farahani, S.K., Teumer, A.,

- 554 Li, Y., Lang, M., Göcmen, B., Pattaro, C., et al. (2023). Imputation-powered 555 whole-exome analysis identifies genes associated with kidney function and 556 disease in the UK Biobank. Nat. Commun. 14, 1287. 557 https://doi.org/10.1038/s41467-023-36864-8.
- 558 26. Teumer, A., Rawal, R., Homuth, G., Ernst, F., Heier, M., Evert, M., 559 Dombrowski, F., Völker, U., Nauck, M., Radke, D., et al. (2011). Genome-wide 560 association study identifies four genetic loci associated with thyroid volume and 561 goiter risk. Am J Hum Genet 88, 664-673. 562 https://doi.org/10.1016/j.ajhg.2011.04.015.
- 563 27. Kang HM (2016). EPACTS: Efficient and Parallelizable Association Container 564 Toolbox.
- Nelson, M.R., Bryc, K., King, K.S., Indap, A., Boyko, A.R., Novembre, J., Briley,
  L.P., Maruyama, Y., Waterworth, D.M., Waeber, G., et al. (2008). The
  Population Reference Sample, POPRES: A Resource for Population, Disease,
  and Pharmacological Genetics Research. Am. J. Hum. Genet. *83*, 347–358.
  https://doi.org/10.1016/j.ajhg.2008.08.005.
- 570 29. Evaluating Human Genetic Diversity (1997). (National Academies Press) 571 https://doi.org/10.17226/5955.
- TRECCANI, M., LOCATELLI, E., PATUZZO, C., and MALERBA, G. (2023). A
  broad overview of genotype imputation: Standard guidelines, approaches, and
  future investigations in genomic association studies. BIOCELL *47*, 1225–1241.
  https://doi.org/10.32604/biocell.2023.027884.
- 576 31. Lachance, J., and Tishkoff, S.A. (2013). SNP ascertainment bias in population 577 genetic analyses: Why it is important, and how to correct it. BioEssays *35*, 578 780–786. https://doi.org/10.1002/bies.201300014.
- 579 32. Geibel, J., Reimer, C., Weigend, S., Weigend, A., Pook, T., and Simianer, H.
  580 (2021). How array design creates SNP ascertainment bias. PLoS One *16*, e0245178. https://doi.org/10.1371/journal.pone.0245178.
- 33. Wojcik, G.L., Fuchsberger, C., Taliun, D., Welch, R., Martin, A.R.,
  Shringarpure, S., Carlson, C.S., Abecasis, G., Kang, H.M., Boehnke, M., et al.
  (2018). Imputation-Aware Tag SNP Selection To Improve Power for LargeScale, Multi-ethnic Association Studies. G3 Genes|Genomes|Genetics 8,
  3255–3267. https://doi.org/10.1534/g3.118.200502.
- 587 34. Elhaik, E. (2022). Principal Component Analyses (PCA)-based findings in population genetic studies are highly biased and must be reevaluated. Sci.
  589 Rep. *12*, 14683. https://doi.org/10.1038/s41598-022-14395-4.
- Bishop, J.A., Sharma, R., and Westra, W.H. (2011). PAX8 immunostaining of
  anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for
  undifferentiated tumors of the head and neck. Hum. Pathol. *4*2, 1873–1877.
  https://doi.org/10.1016/j.humpath.2011.02.004.
- 59436.Suzuki, A., Hirokawa, M., Takada, N., Higuchi, M., Yamao, N., Kuma, S., Daa,595T., and Miyauchi, A. (2015). Diagnostic significance of PAX8 in thyroid596squamous cell carcinoma. Endocr. J. 62, 991–995.597https://doi.org/10.1507/endocrj.EJ15-0226.
- 37. Ozcan, A., Shen, S.S., Hamilton, C., Anjana, K., Coffey, D., Krishnan, B., and Truong, L.D. (2011). PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod. Pathol. 24, 751–764. https://doi.org/10.1038/modpathol.2011.3.

#### 604 Figure Legends

Figure 1. Overview of the designed workflow. Variants colored in dark green represent the variants imputed in the intermediate imputation phase (first imputation), while variants colored in white are imputed from general 1000G reference panel in both two-step and conventional imputation.

Figure 2. Genetic PCA of the included cohorts in the workflow. The samples are colored by the cohorts with their unique array type. Panel A and B show the first four genetic components of the conventional imputation approach (variance explained for the components combined is 0.34). Panels C and D show the first four components of the proposed approach (variance explained for the components combined is 0.17).
Figure 3. Median R2 of the imputation outcomes of genotype data of the included

615 cohorts, using conventional (dotted) and two-step imputation (full line).

Figure 4. Boxplots grid of the absolute difference in allele frequency (AF) between conventional and two-step imputation outcomes for the included cohorts. Each column represents an allele frequency group (rare, low, common) and each row represents one of the included cohorts.

620 Figure 5. Manhattan plot of the GWAS analysis of goiter risk using combined two-621 step imputation genotypes (A) and conventional imputation and meta-analysis 622 approach (B). Variants are plotted on the x axis and  $-\log_{10}$  p-values of the 623 association testing on the y axis. Associations significant after correction for multiple testing (p < 5  $\times 10^{-8}$ ) are colored in red. Regional association results and 624 625 recombination rates for the XKR6 gene from two-step imputation GWAS are 626 presented in part C, -log<sub>10</sub> p-values (y-axis) of the single nucleotide variants 627 according to their chromosomal positions (x-axis) with lead variant (rs7005680) is 628 shown as a purple diamond.

**Figure 6.** Manhattan plot of the GWAS analysis of log thyroid volume using combined two-step imputation genotypes (A) and conventional imputation and metaanalysis approach (B). Variants are plotted on the x axis and  $-\log_{10}$  p-values of the association testing on the y axis. Associations significant after correction for multiple testing (p < 5 ×10<sup>-8</sup>) are colored in red. Regional association results and recombination rates for the *NRG1* gene from conventional imputation GWAS are presented in part C,  $-\log_{10}$  p-values (y-axis) of the single nucleotide variants

- 636 according to their chromosomal positions (x-axis) with lead variant (rs7000397) is
- 637 shown as a purple diamond.

## 639 Tables

**Table 1.** Genotype concordance (number of matching genotypes/total number of

641 genotypes) of the hard call imputed genotypes with sequenced data for homozygous

642 reference (HomRef), homozygous alternative (HomAlt), and heterozygous (Het) calls,

all variants followed by stratification by minor allele frequency (MAF) group of the

644 imputed data. (n) represents number of variants represented per group in both

645 imputed and sequenced genotypes.

646

Group	All variants		MAF 0.05-0.5		MAF 0.01-0.05		MAF 0.0-0.01			
	Conventional	Two-step	Conventional	Two-step	Conventional	Two-step	Conventional	Two-step		
HomRef	0.9963	0.9962	0.9913	0.9910	0.9959	0.9988	0.9993	0.9994		
	(618,453,288)	(613,997,680)	(224,034,629)	(222,769,137)	(171,621,821)	(183,771,150)	(222,756,838)	(207,703,823)		
Het	0.9814	0.981	0.9897	0.9893	0.9424	0.9418	0.7875	0.7525		
	(116,274,486)	(116,144,961)	(105,647,496)	(105,617,755)	(8,530,966)	(8,903,479)	(2,139,474)	(1,695,994)		
HomAlt	0.9783	0.9787	0.9802	0.9807	0.7979	0.7862	0.2512	0.1389		
	(21,587,792)	(21,408,323)	(21,463,336)	(21,290,637)	(128,442)	(124,359)	(5,149)	(2,369)		

647

## **Table 2.** Cohort characteristics for GWAS analysis of thyroid volume and goiter risk.

649 BSA: body surface area.

Cohort	Ν	Age	Sex	BSA	Current	Log thyroid volume	Goiter
		(mean ± SD)		(mean ± SD)	smoker	(mean ± SD)	cases(%)
SHIP START	3,611	49.1 (16.3)	47.4% Male,	1.9 (0.2)	31.6%	2.9 (0.5)	1322 (36.6%)
			52.6% Female				
SHIP-TREND	784	49.2 (13.9)	51.5% Male,	1.9 (0.2)	22.2%	2.9 (0.4)	253 (32.3%)
			48.5% Female				
SHIP-TREND	2,499	51.3 (16)	56.9% Male,	1.9 (0.2)	29.8%	2.9 (0.4)	737 (29.5%)
batch II			43.1% Female				

650

- 652 Table 3. Loci lead SNVs with the strongest association with thyroid volume (A), and
- 653 goiter risk (B) in GWAS analysis using both two-step imputed and conventionally 654 imputed genotypes.
- 655 Novel loci are marked in bold. A1: coded allele, AF: frequency of coded allele, SE:
- 656 standard errors, R2: linkage disequilibrium in the top SNVs of the same locus in both
- 657 imputation outcomes
- 658

A) Volume		Two-step imputation GWAS					Conventional imputation GWAS meta-analysis								
Locus	Lead SNP	CHR	A1	AF	Effect	SE	P-value	Lead SNP	CHR	A1	AF	Effect	SE	P-value	R2
CAPZB	rs4911994	1	Α	0.64	0.057	0.01	1.63E-18	rs4911994	1	Α	0.63	0.055	0.01	5.93E-19	Same SNP
	rs10799824	1	А	0.15	0.086	0.01	1.82E-22	rs12410532	1	Т	0.14	0.092	0.01	6.14E-24	0.978
ΡΑΧ8	rs7560701	2	С	0.48	-0.036	0.01	1.12E-08	rs1110839	2	Т	0.48	0.038	0.01	6.35E-10	0.576
IGFBP5	rs2712172	2	Α	0.27	0.041	0.01	1.46E-08	rs2712172	2	Α	0.26	0.039	0.01	1.95E-08	Same SNP
NRG1	rs7000397	8	G	0.35	0.035	0.01	5.22E-08	rs7000397	8	G	0.34	0.04	0.01	1.42E-08	Same SNP
TG	rs114322847	8	Т	0.03	0.122	0.02	1.90E-09	rs79676842	8	Т	0.03	0.135	0.02	2.06E-11	1
FAM227B	rs17477923	15	С	0.26	0.054	0.01	9.55E-14	rs73398264	15	Т	0.75	-0.052	0.01	7.73E-14	1
MAFTRR	rs3813579	16	A	0.53	0.056	0.01	2.57E-19	rs562609617	16	G	0.66	-0.064	0.01	1.85E-22	0.413
B) Goiter		Two-step imputation GWAS					Conventional imputation GWAS meta-analysis								
Locus	Lead SNP	CHR	A1	AF	Effect	SE	P-value	Lead SNP	CHR	A1	AF	Effect	SE	P-value	R2
CAPZB	rs4911994	1	Α	0.64	0.614	0.68	8.89E-14	rs4911994	1	Α	0.62	0.302	0.04	1. 13E- 13	Same SNP
	rs10799824	1	Α	0.15	0.135	0.19	6.68E-16	rs12410532	1	Т	0.14	0.450	0.06	1.25E-15	0.978
XKR6	rs7005680	8	Т	0.35	-0.218	0.04	7.98E-09	rs11778398	8	Т	0.46	-0.200	0.04	4.35E-07	0.761
FAM227B	rs75929244	15	Т	0.24	0.321	0.04	2.17E-13	rs73398264	15	Т	0.75	-0.313	0.04	1.61E-12	0.897
MAFTRR	rs3813579	16	GT	0.35	0.29	0.04	4.44E-13	rs562609617	16	G	0.34	0.064	0.01	1.85E-22	Same SNP



medRxiv preprint doi: https://doi.org/10.1101/2024.11.21.24317711; this version posted November 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has gramed medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed whout permission.













# Туре

- Conventional
- Two\_step

# Source

- GANI\_MED
- SHIP START
- SHIP START II
- SHIP-TREND
- SHIP-TREND batch II



![](_page_26_Figure_0.jpeg)

![](_page_26_Figure_1.jpeg)

B)

C)

![](_page_26_Figure_3.jpeg)

![](_page_27_Figure_0.jpeg)

C)

![](_page_27_Figure_2.jpeg)